Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.53 |
| ▸ | IDH1 | O75874 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | FADS1 | O60427 | 1/20 | 0.40 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.39 |
| ▸ | CTSG | P08311 | 1/20 | 0.39 |
| ▸ | CMA1 | P23946 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9105102 | 1.00 | NOTUM (0.53) | NOTUMIDH1ALOX5P2RX7CNR2 | |
| SCHEMBL7123162 | 0.88 | NOTUM (0.46) | NOTUMIDH1ALOX5P2RX7CNR2 | |
| SCHEMBL7123171 | 0.88 | NOTUM (0.46) | NOTUMIDH1ALOX5P2RX7CNR2 | |
| SCHEMBL9109062 | 0.83 | CNR2 (0.53) | P2RX7CNR2FFAR2 | |
| SCHEMBL9109050 | 0.83 | CNR2 (0.53) | P2RX7CNR2FFAR2 | |
| SCHEMBL9107908 | 0.81 | P2RX7 (0.54) | NOTUMP2RX7 | |
| SCHEMBL9107918 | 0.81 | P2RX7 (0.54) | NOTUMP2RX7 | |
| SCHEMBL9340692 | 0.81 | KDM4E (0.45) | P2RX7KMT2A | |
| SCHEMBL289664 | 0.80 | P2RX7 (0.51) | NOTUMP2RX7CNR2KMT2A | |
| SCHEMBL289579 | 0.80 | P2RX7 (0.51) | NOTUMP2RX7CNR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2384320-B1 | PYRROLIDINE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2015-03-04 | — | — | EP | disclosed |
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20030176465-A1 | Cyclic amino acid derivatives | MERCK PATENT GMBH (DE) | 2003-09-18 | — | — | US | disclosed |
| EP-1301506-A1 | CYCLIC AMINO ACID DERIVATIVES | MERCK PATENT GmbH (DE) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002006269-A1 | CYCLIC AMINO ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176465-A1 | Cyclic amino acid derivatives | F5, F11, F2 | NOTUM 4067/4885IDH1 2542/4885ALOX5 441/4885 |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | NOTUM 2241/4885IDH1 4245/4885ALOX5 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.